Merck KGaA has reported proteolysis targeting chimera (PROTACs) comprising an E3 ubiquitin ligase-binding moiety covalently linked to mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1)-targeting moiety. They are described as potentially useful for the treatment of cancer.
Nippon Shinyaku Co. Ltd. has disclosed compounds inhibiting binding between r(CUG) repeats in DMPK (DM1) and MBNL protein reported to be useful for the treatment of myotonic dystrophy 1.
John Squires, the recently anointed director of the U.S. Patent and Trademark Office, has determined that a machine learning (ML) patent application met the standard for patent subject matter eligibility, an outcome that seems to bode well for ML-based patent applications going forward.
Merck KGaA has prepared and tested new antibody-drug conjugates (ADCs) comprising monoclonal antibodies targeting sodium-dependent phosphate transport protein 2B (SLC34A2; NaPi-2b) linked to exatecan through a β-glucuronidase cleavable linker. They are described as potentially useful for the treatment of ovarian and non-small-cell lung cancer.
Shanghai Apeiron Biotechnology Co. Ltd. has reported selenium-containing heterocyclic compounds acting as DNA polymerase theta (POLθ, POLQ) inhibitors potentially useful for the treatment of cancer.
AC Immune SA has synthesized thiazolo[5,4-c]pyridine-4(5H)-one derivatives acting as TAR DNA-binding protein 43 (TARDBP; TDP-43) aggregation ligands reported to be useful for the diagnosis of amyotrophic lateral sclerosis, Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, limbic-predominant age-related TDP-43 encephalopathy and traumatic encephalopathy.
University of Basel and NXI Therapeutics AG have jointly patented compounds targeting bromodomain-containing protein 3 (BRD3; RING3-like protein) to inhibit expression of coronin-1. They are described as potentially useful for the treatment of transplant rejection, autoimmune diseases, inflammation, infections and lymphoproliferative disorders.
Genescience Pharmaceuticals Co. Ltd. has discovered new tyrosinase (TYR) inhibitors acting as melanin inhibitors potentially useful for the treatment of skin hyperpigmentation.
RSS
